All In Biotech

Drug Trial Radar · NCT04747613

Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria

An Open Label, Multicenter Roll-over Extension Program (REP) to Characterize the Long-term Safety and Tolerability of Iptacopan (LNP023) in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Completed PNH Phase 2 and Phase3 Studies With Iptacopan

Last checked: Nov 20, 2026Latest source record: Aug 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

208

Actual

Start

Jul 27, 2021

Primary completion

Oct 18, 2027

Study completion Oct 18, 2027

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Feb 10, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an open-label, single arm, multicenter, roll-over extension study to characterize long-term safety, tolerability and efficacy of iptacopan and to provide access to iptacopan to patients with PNH who have completed Novartis-sponsored Phase 2 or 3 studies with iptacopan

Conditions

  • Paroxysmal Nocturnal Hemoglobinuria

Interventions

  • IptacopanDrug

    Taken orally b.i.d. Dosage supplied: 200 mg Dosage form: hard gelatin capsule Route of administration: oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants with adverse eventsTime frame: Up to 74 months

Locations

60 sites in 17 countries. Site status is shown where the registry gives one.

  • City Of Hope National Med Center

    Duarte, California

  • City Of Hope

    Duarte, California

  • USC Norris Cancer Center

    Los Angeles, California

  • Univ Cali Irvine ALS Neuromuscular

    Orange, California

  • Univ of California Irvine (Chao Family Comprehensive Cancer Center)

    Orange, California

  • Lakes Research

    Miami Lakes, Florida

  • Augusta University Georgia

    Augusta, Georgia

  • Augusta University

    Augusta, Georgia

  • Montefiore Medical Center

    The Bronx, New York

  • Cleveland Clinic Foundation

    Cleveland, Ohio

  • Prisma Health Upstate

    Greenville, South Carolina

  • Novartis Investigative Site

    Santo André, São Paulo, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil

  • Novartis Investigative Site

    Beijing, China

  • Novartis Investigative Site

    Tianjin, China

  • Novartis Investigative Site

    Tianjin, China

  • Novartis Investigative Site

    Brno, Czechia

  • Novartis Investigative Site

    Ostrava, Poruba, Czechia

  • Novartis Investigative Site

    Lille, France

  • Novartis Investigative Site

    Nantes, France

  • Novartis Investigative Site

    Nice, France

  • Novartis Investigative Site

    Paris, France

  • Novartis Investigative Site

    Toulouse, France

  • Novartis Investigative Site

    Aachen, Germany

  • Novartis Investigative Site

    Essen, Germany

  • Novartis Investigative Site

    Hamburg, Germany

  • Novartis Investigative Site

    Riesa, Germany

  • Novartis Investigative Site

    Ulm, Germany

  • Novartis Investigative Site

    Dresden, Saxony, Germany

  • Novartis Investigative Site

    Ascoli Piceno, AP, Italy

  • Novartis Investigative Site

    Avellino, AV, Italy

  • Novartis Investigative Site

    Florence, FI, Italy

  • Novartis Investigative Site

    Milan, MI, Italy

  • Novartis Investigative Site

    Roma, RM, Italy

  • Novartis Investigative Site

    Torino, TO, Italy

  • Novartis Investigative Site

    Bassano del Grappa, VI, Italy

  • Novartis Investigative Site

    Fukushima, Japan

  • Novartis Investigative Site

    Ishikawa, Japan

  • Novartis Investigative Site

    Kyoto, Japan

  • Novartis Investigative Site

    Niigata, Japan

Showing 40 of 60 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.